These investigators assessed the efficacy--or lack thereof--from HER-2 targeted therapies that were evaluated in relation to ERBB2 variants using a cancer genome screening project. Share on Facebook.

Higher TIL levels predict better survival in early ERBB2-positive breast cancer, supporting treatment de-escalation for ...

Each ERBB receptor has distinct locations and numbers of tyrosine phosphorylation sites on its C-terminal tails; there are twelve on ERBB1, six on ERBB2, and eleven on ERBB3 (Jones et al.

Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved The ...